For example, T-DM1 efficacy is dependent on the level of expression of HER2 on cancer cells and it is known that patients who express HER2, defined by an IHC score of 3+, exhibit more frequent responses than patients with reduced levels [196,197]. The gene discussed is ERBB2; the disease is cancer.